Hongxia Zhang
Independent Expert
Experienced, driven translational science lead, thriving to convert innovation to transformative medicine. Leader with agility, high sense of urgency, personal initiative, and a track record of success. Wide range of drug R&D experience spanning early discovery, translational research (forward/reverse), and clinical development (early/late). Expert knowledge in Oncology and Immunology across multiple treatment modalities (ICB, bispecific, ADC, cancer vaccine, targeted, and cell therapy). Formerly at Century Therapeutics.
Seminars
Advancing NK-based therapies from preclinical proof-of-concept to meaningful clinical outcomes depends on identifying the right patients and monitoring their responses effectively. Predictive biomarkers, translational analytics, and innovative assay platforms are critical to reduce trial risk, guide dosing, and validate therapeutic mechanisms. This workshop explores state-of-the-art strategies to integrate biomarker discovery and translational science into NK therapy development to de-risk programs and speed regulatory and clinical milestones.
Join this workshop to:
- Understand emerging biomarkers for patient selection, persistence, and therapeutic response in autoimmunity and oncology
- Explore cutting-edge analytical tools, single-cell sequencing, spatial transcriptomics, and functional NK assays to uncover actionable insights
- Review case-based examples of how translational strategies can refine trial design, optimize dosing, and improve go/no-go decisions
